Incidence of Bladder Cancer in Patients Undergoing Radiotherapy for Prostate Cancer.

Area of Science:

• Oncology
• Radiation Oncology
• Cancer Research

Background:

• Radiotherapy is a validated prostate cancer treatment.
• The link between radiotherapy, secondary pelvic cancers, and toxicity remains debated.
• This study investigates these relationships in prostate cancer patients.

Purpose of the Study:

• To analyze the occurrence of second pelvic primary malignancy after prostate cancer radiotherapy.
• To assess the clinical toxicity associated with radiotherapy treatment.
• To determine if radiotherapy modality influences secondary malignancy risk and toxicity.

Main Methods:

• Retrospective study of 317 prostate cancer patients treated between 2007-2017.
• Collected data on predictor variables, side effects, and second pelvic primary malignancy.
• Analyzed relationships between radiotherapy type, secondary malignancy, and clinical toxicity over a 10-year follow-up.

Main Results:

• 5.4% of patients developed a second pelvic primary malignancy (bladder, colon).
• Statistically significant associations found between radiotherapy type and secondary malignancy (p=0.003).
• Chronic toxicity was also significantly associated with radiotherapy type (p=0.011).

Conclusions:

• The chosen radiotherapy modality is a significant factor in the development of second pelvic primary malignancies.
• Radiotherapy type is also linked to the occurrence of chronic adverse effects.
• Findings highlight the importance of considering radiotherapy modality in risk assessment for prostate cancer patients.